Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Pulse Biosciences (PLSE) Operating Expenses (2020 - 2025)

Pulse Biosciences has reported Operating Expenses over the past 6 years, most recently at $20.5 million for Q3 2025.

  • Quarterly results put Operating Expenses at $20.5 million for Q3 2025, up 49.78% from a year ago — trailing twelve months through Dec 2025 was $58.8 million (up 4.47% YoY), and the annual figure for FY2024 was $56.3 million, up 29.11%.
  • Operating Expenses for Q3 2025 was $20.5 million at Pulse Biosciences, up from $20.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for PLSE hit a ceiling of $20.5 million in Q3 2025 and a floor of $8.7 million in Q4 2022.
  • Median Operating Expenses over the past 5 years was $14.8 million (2021), compared with a mean of $14.8 million.
  • Biggest five-year swings in Operating Expenses: tumbled 46.25% in 2022 and later surged 72.91% in 2025.
  • Pulse Biosciences' Operating Expenses stood at $16.3 million in 2021, then tumbled by 46.25% to $8.7 million in 2022, then surged by 43.46% to $12.5 million in 2023, then soared by 61.66% to $20.3 million in 2024, then grew by 0.95% to $20.5 million in 2025.
  • The last three reported values for Operating Expenses were $20.5 million (Q3 2025), $20.3 million (Q2 2025), and $18.0 million (Q1 2025) per Business Quant data.